Liver, colon cancer cells thwarted by compounds derived from hops

The plant that adds flavor, color and bitterness to beer also produces a primary compound that thwarts cancer cells, and two important derivatives of the compound do as well, new research at Oregon State University shows. Unlike the primary compound, xanthohumol, known as XN, the derivatives don't metabolize into phytoestrogens.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Related Links:

Conclusions: While case reports cannot be considered as proof of efficacy, these cases added to others of patients treated with the same method would suggest that this is a viable option for those patients whose disease cannot be treated successfully with other modalities. PMID: 31202206 [PubMed - in process]
Source: Alternative Therapies in Health and Medicine - Category: Complementary Medicine Authors: Tags: Altern Ther Health Med Source Type: research
ConclusionsCNS-RF is a relevant measure of prognosis in patients who have already achieved a period of remission. Providing an updated estimation of prognosis in the years following diagnosis may improve the survivors’ quality of life and access to credit or insurance.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
Immunotherapy using chimeric antigen receptor (CAR)-engineered lymphocytes has shown impressive results in leukemia. However, for solid tumors such as colorectal cancer (CRC), new preclinical models are needed that allow to test CAR-mediated cytotoxicity in a tissue-like environment. Here, we developed a platform to study CAR cell cytotoxicity against 3-dimensional (3D) patient-derived colon organoids. Luciferase-based measurement served as a quantitative read-out for target cell viability. Additionally, we set up a confocal live imaging protocol to monitor effector cell recruitment and cytolytic activity at a single organ...
Source: EMBO Journal - Category: Molecular Biology Authors: Tags: Cancer, Immunology, Methods & Resources Source Type: research
Sir — We thank Laverty et al. for their correspondence and congratulations in response to our work.1 Please accept our apologies for the discrepancy in polyp categorisation. The revised polyp data in line with National Bowel Cancer Screening programme, the European Society of Gastrointestinal and Abd ominal Radiology (ESGAR) consensus guidelines2 and other published studies is as follows3,4: the total polyp detection rate was 13.5% (241 polyps) in 170 patients; 153 (63.5%) polyps were ≥10 mm in size compared to 88 (36.5%) measuring between 6–9 mm.
Source: Clinical Radiology - Category: Radiology Authors: Tags: Correspondence Source Type: research
AbstractPurpose of ReviewAdjuvant therapy for 6  months is the standard of care for stage III colon cancer. The use of oxaliplatin-based therapy over fluoropyrimidine alone increases toxicity, including dose-dependent peripheral neuropathy. Evaluation of a shorter duration of adjuvant therapy was therefore warranted, aiming to reduce toxicity wh ile maintaining clinical efficacy.Recent FindingsThe International Duration Evaluation of Adjuvant chemotherapy (IDEA) collaboration was a pivotal prospective pooled analysis of 6 randomized phase III trials across 12 countries. IDEA evaluated the non-inferiority of 3 versus 6...
Source: Current Colorectal Cancer Reports - Category: Cancer & Oncology Source Type: research
AbstractPurpose of ReviewColorectal cancer is the third most common cancer worldwide with a high mortality rate at the advanced stages of the disease. Treatment options are dependent on the stage of the disease, patients ’ performance status, and the specific molecular makeup of the tumor. Adding an anti-epidermal growth factor receptor monoclonal antibody (anti-EGFR mAb) to conventional chemotherapy in molecularly selected patients (i.e., RAS wild-type) leads to a survival advantage. We aim to review the latest e vidence on the influence of primary tumor location (PTL) on treatment response to chemotherapy combined ...
Source: Current Colorectal Cancer Reports - Category: Cancer & Oncology Source Type: research
AbstractCancer is a deadly disease which requires a very complex and costly treatment. Microarray data classification plays an important role in cancer treatment. An efficient gene selection technique to select the more promising genes is necessary for cancer classification. Here, we propose a Two-stage MI-GA Gene Selection algorithm for selecting informative genes in cancer data classification. In the first stage, Mutual Information based gene selection is applied which selects only the genes that have high information related to the cancer. The genes which have high mutual information value are given as input to the seco...
Source: Journal of Medical Systems - Category: Information Technology Source Type: research
AbstractSuperficially serrated adenoma (SuSA) is a recently proposed subtype of colorectal serrated lesion. We here report a sigmoid colon cancer derived from SuSA, which exhibited aggressive clinical behavior. Endoscopically, the tumor appeared as a superficial elevated lesion with a large nodule. Histological examination of the surgically resected material showed tubular adenocarcinoma associated with SuSA. Although tumor invasion was limited to the submucosal layer, lymph node and extranodal metastases were detected. The patient subsequently developed peritoneal metastases and died 15  months after surgery. Molecul...
Source: Virchows Archiv - Category: Pathology Source Type: research
This study demonstrated promising anticancer and antibacterial effects of Artemia salina egg extracts. Our results suggest that pure bioactive compounds obtained from Artemia salina eggs can provide new insights into the mechanisms of colon and skin cancer, as well as Pseudomonas aeruginosa inhibition. PMID: 31198432 [PubMed]
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
In this study, we developed a novel anti-HER2 monoclonal antibody (mAb), H2Mab-41 (IgG2b, kappa), and the antitumor activity of H2Mab-41 was investigated using mouse xenograft models. Caco-2 cells (human colon cancer cell line), which expresses HER2, were subcutaneously implanted into the flanks of nude mice. H2Mab-41 and control mouse IgG were injected three times into the peritoneal cavity of mice. H2Mab-41 significantly reduced tumor development of Caco-2 xenograft in comparison with the control mouse IgG on days 5, 8, 11, 15, and 19. Taken together, these results suggest that H2Mab-41 is useful for antibody therapy aga...
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - Category: Microbiology Tags: Monoclon Antib Immunodiagn Immunother Source Type: research
More News: Cancer | Cancer & Oncology | Colon Cancer | Colorectal Cancer | Liver | Pharmaceuticals | Urology & Nephrology